VeonGen Therapeutics GmbH

VeonGen Therapeutics GmbH is a young and innovative gene therapy company founded in 2017 as a spin-off of the Ludwig-Maximilians-University Munich. The company focuses on developing novel therapeutics for previously untreatable ophthalmic diseases using adeno-associated virus (AAV)-based technology platforms. Its mission is to provide patients with new treatment options that address significant unmet medical needs.